Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1479-1485

  Thompson, Andrew E ^a,b   Rieder, Scott W ^a   Pope, Janet E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BOWEN DISEASE; BREAST CANCER; CANCER RISK; CARCINOID; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DISEASE SEVERITY; DRUG FATALITY; ENDOMETRIUM CANCER; HERPES ZOSTER; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INFECTION; LUNG CANCER; LUNG TUBERCULOSIS; MELANOMA; META ANALYSIS; MULTIPLE MYELOMA; NEOPLASM; OPPORTUNISTIC INFECTION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SEPSIS; TONGUE CANCER; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956215758     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30310     Document Type: Article

References (28)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84. (Pubitemid 351847559)
2. Askling J, Dixon W,. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-44. (Pubitemid 351339884)
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
4. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists [published erratum appears in Ann Rheum Dis 2007;66:1548]. Ann Rheum Dis 2007; 66: 1339-44. (Pubitemid 47492478)
5. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ,. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177-83.
6. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Onkologie 2000; 23: 597-602. (Pubitemid 32046061)
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
8. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ,. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008; 88: 156-75. (Pubitemid 351210558)
9. Review Manager (RevMan) software for preparing and maintaining Cochrane Reviews: version 5.0. Copenhagen (Denmark): Cochrane Collaboration; 2009.
10. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [published erratum appears in Arthritis Rheum 2010;62:3005]. Arthritis Rheum 2009; 60: 2272-83.
11. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81. (Pubitemid 38296553)
12. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
13. Keystone E, van der Heijde D, Mason D Jr, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study [published erratum appears in Arthritis Rheum 2009;60:1249]. Arthritis Rheum 2008; 58: 3319-29.
14. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
15. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37. (Pubitemid 43122183)
16. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:76 and N Engl J Med 2001;344:240]. N Engl J Med 2000; 343: 1586-93. (Pubitemid 32162981)
17. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43. (Pubitemid 39488667)
18. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al, and the Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 1467-74.
19. Van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial. Lancet 2009; 374: 459-66.
20. Okada SK, Siegel JN,. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis [letter]. JAMA 2006; 296: 2201-2. (Pubitemid 44708042)
21. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2757-64. (Pubitemid 44497754)
22. Wolfe F, Michaud K,. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51. (Pubitemid 38725085)
23. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95. (Pubitemid 47502734)
24. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20. (Pubitemid 41623850)
25. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6. (Pubitemid 41623851)
26. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11. (Pubitemid 38608061)
27. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86. (Pubitemid 29135800)
28. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602. (Pubitemid 32162982)